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Abstract: The scope of this research was determination of Rhodococcus equi isolates and antimicrobial susceptibilities in nasal swab
specimen taken from animals between 0 and 6 months of age period. R. equi was identified from 10 isolates (11.1%) by automatic
identification device. The verification of isolates were conducted by 16S ribosomal RNA PCR. VapA gene presence was detected in
two (20%) isolates and multidrug resistance was identified against 11 antimicrobials. The antimicrobial resistance to macrolides and
rifampin is arising worldwide since the excessive usage of the chemotherapeutics in various breeding farms just by evaluating monitoring
outcomes. These results exhibit the presence of resistant strains among equine populations. The development of fast, economical and
highly specific diagnostic technique against the threat of R. equi is essensial for better understanding of gene expressions related to
resistance and development of effective immunization.
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1. Introduction
Foal pneumonia is a significant cause of malady and deaths
in horses. Although various multiple microorganisms
causing pneumonia have been identified in horses,
Rhodococcus equi is regarded as the most important agent
of severe pneumonia [1]. The prevalence and lethality rate
of R. equi pneumonia is frequently high and the veterinary
practitioners lack the tools required for effective early
diagnosis or prevention. Long-term and high-cost therapies
(frequent prophylactic antibiotic use in endemic breeding
farms) are the most important obstacles for treatment of
R. equi pneumonia that cause major economic losses for
equine breeding farms [1,2,3]. In addition, in these farms
where the disease is endemic, the diagnosis is made mostly
by hypothesis of farm managers and veterinarians. This is
due to the fact that the tracheobronchial aspiration (TBA)
technique [4], which is accepted as the gold standard in
the diagnosis, can threaten the health of the foals.
The clinical symptoms are usually seen in foals younger
than 4 months in R. equi pneumonia [4]. R.equi is a grampositive, facultative intracellular, aerobic, nonmotile,
nonspore-forming coccobacilli that causes chronic
granulomatous pneumonia and lung abscesses [5]. First
isolated by Magnusson in Sweden in 1923, this bacterium
spreads worldwide and can often be isolated from soil and

miscellaneous environmental specimen [6]. Frequently
isolated from cervical lymph nodes of pigs, this bacterium
can infect humans and many other mammal species
infrequently following immunosuppression. Following
infection in these rare cases; lung abscess, granulomatous
pneumonia, lymphadenitis (mesenteric, bronchial or
cervical lymph nodes), infected wounds and abscesses in
different parts of the body is formed [5].
The pathogenicity of R. equi depends on the
plasmids. Although the functions encoded in plasmids
in environmental Rhodococci are generally catabolic, R.
equi plasmids provide colonization of the host [7,8]. Its
pathogenicity and duplication in macrophage cells are
due to the existence of a large plasmid of about 85–90
kb [6,9,10]. Pathogenicity is regulated by vap (virulence
associated proteins) gene located in the PAI (pathogenity
island) region acquired by horizontal gene transfer of this
plasmid. There are seven virulence associated protein
genes (vapA-B-C-D-E-G-H) and three truncated virulence
associated protein pseudogenes (vapF-I-X) [11]. Among
these proteins, vapA is essential for bacterial pathogenicity
in foals [12]. PAI contains a number of non-vap genes
as well as vap genes. Among these genes, the vir operon
contains virR and virS regulators that initiate the expression
of PAI [13,14]. The virulence plasmid also plays a role in
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host selectivity. To date, 3 host-specific plasmids have been
identified. Circular pvapA has been associated with horse
isolates; circular pvapB with porcine isolates and linear
plasmid pvapN with bovine isolates [12]. The presence of
all three types of plasmids in human isolates [15] coincides
with the fact that humans are an opportunist host for R. equi
and that the infection is of zoonotic origin. The scope of this
study was to determine the presence of R. equi in the foals
by conventional and molecular methods and to investigate
the antibacterial resistance of the R. equi.
2. Materials and methods
Nasal swab specimens were collected from 90 foals in June
2016 from Southern part of Marmara region and Northern
part of Aegean region, Turkey. The foals were between 1
month and 6 months of age period from 4 horse farms.
The swabs were taken from the left or right ventral meatus
of nasal passage. The swab specimens were transferred to
laboratory in the cold chain.
2.1. Phenotypic identification
The samples (n = 90) brought to the laboratory were
immediately inoculated in R. equi selective medium
[NANAT: nalidixic acid (20 μg/mL), novobiocin (25 μg/
mL), actidione (cycloheximide) (40 μg/mL) and potassium
tellurite (0.005%)] and incubated at 37 ºC for 48 h.
Macroscopic and microscopic morphology of salmon
coloured bacterial colonies were examined, and gram
staining and biochemical tests (catalase, oxidase, urease,
lipase, phosphatase, CAMP with S. auerus ATCC 25923)
were performed.
2.2. Genotypic identification
2.2.1. Primers
The 16S rRNA primers used in the study were determined
as indicated by Mir et al. [16], vapA and vapB primers by
Al-Graibawi and Mohammed [17].
2.2.2. Standard strains
R. equi ATCC 6939 and E. coli ATCC 25922 were used as the
quality control strains in biochemical and molecular tests.
2.2.3. Rhodococcus equi 16S rRNA PCR step
DNA extraction of R. equi isolates was performed according
to the protocol reported by Mir et al. [16]. The thermal
cycling of PCR conditions was as follows: predenaturation
at 94 ºC for 5 min followed by 35 cycles of denaturation at
94 ºC for 30 s, 30 s annealing at 56 ºC, 30 s extension at 72
ºC and 5 min at 72 ºC final extension stages. PCR products
were electrophoresed in 1% agarose gel and visualised on
Vilber Lourmat UV transilluminator (Vilber Lourmat,
Collégien, France). The amplicon length of 450 bp was
observed for R. equi.
2.2.4. R. equi vapA and vapB gene presence
The molecular characterization of R. equi 16S rRNA positive
samples were performed by the second PCR specific for

vapA and vapB genes according to the protocol in a previous
study [17]. The thermal cycling of PCR conditions was as
follows: predenaturation at 94 ºC for 5 min followed by 35
cycles of denaturation at 94 ºC for 1 min, 30 s annealing
at 48 ºC, 1 min extension at 72 ºC and 5 min at 72 ºC final
extension stages. PCR products were electrophoresed on
2% agarose gel and gel imaging was performed on Vilber
Lourmat UV transilluminator. Amplicons were 286 bp for
the R. equi vapA gene and 477 bp for the vapB gene.
2.3. Determination of antimicrobial susceptibilities of
isolates
R. equi colonies were inoculated into tryptic soy broth and
incubated at 37 ºC for 8 h (1 × 108 cfu/mL) until turbidity
reached. Bacteria suspensions were diluted in the ratio of
1:10. Thus, the bacterial inoculum was adjusted to 1 × 107
cfu/mL concentration.
A hundred µL of cation adjusted Mueller–Hinton broth
was added to all wells in the microplate, then 100 µL of 256
µg/mL antibiotic solution was added to the first wells and
the antibiotic concentration in the first well was adjusted
to 128 µg/mL. Dilution was performed by taking 100 µL
of this concentration and transferring it to 128 µg/mL.
This process was repeated to a well of 0.0625 µg/mL and
the last 100 µL was discarded. The final concentrations of
antibiotic agents in microplates were between 0.0625–128
µg/mL. Five µL of the bacterial inoculum in a dilution
of 1 × 107 cfu/mL was poured all wells. Thus, the final
concentration of the bacterial inoculum was adjusted to 5
× 105 cfu/mL. The agar plates were incubated at 35 ºC for 18
to 24 h. The lowest antibiotic concentration without growth
was recorded as the MIC value [18,19]. Amoxicillin,
streptomycin, kanamycin, amoxicillin clavulanic acid,
amikacin, clarithromycin, azithromycin, cefoxitin,
clindamycin, rifampin, erythromycin (Oxoid Limited,
Hampshire, UK) were used to determine the antibiotic
susceptibility of the isolates.
3. Results
3.1. Phenotypic findings
Smooth colonies of salmon pink colour were observed in
10 of the nasal swab samples (n = 10) that were grew on
NANAT media and incubated at 37 ºC for 48 h. All isolates
(n = 10) were found as gram-positive, catalase, urease,
lipase, phosphatase and CAMP test (S. aureus ATCC
25923) positive, and oxidase negative. The isolates were
loaded onto BD Phoenix instrument using PMIC/ID-87
panel kits (Becton Dickinson Company, Franklin Lakes,
NJ, USA) and all of them were confirmed as R. equi.
3.2. Genotypic findings
PCR amplifications of 10 identified 16S rRNA samples
were visualized by agarose gel electrophoresis. All R. equi
isolates (n = 10) were 16S rRNA positive in the 450 bp
fragment length as shown in Figure 1.
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Specimens found positive by 16S rRNA PCR were
investigated for the vapA gene, and the formation of the
vapA in the 286 bp band gap was detected in 2 (20%) of 10
(isolate no: 53 and 57) samples as shown in Figure 2.
Samples found positive by 16S rRNA PCR were
investigated for the vapB gene but no positive sample was
detected. The PCR results of the isolates are given in Table 1.
The susceptibility of 10 R. equi isolates against
11 different antimicrobial agents was determined by

microdilution technique. The MIC values of R. equi
isolates are shown in Table 2.
The MIC values indicating the antibiotic susceptibility
of R. equi (n = 10) isolates identified in our study showed
that the MIC range was ≤0.25 – ≥256. The lowest MIC50
value was 2 µg/mL in erythromycin and the highest MIC90
value was ≥128 µg/mL in kanamycin and amikacin. The
antibiogram results of R. equi (n = 10) isolates identified
according to CLSI standards presented that 80% of the

Figure 1. 16S rRNA electrophoresis figure; M: 100bp DNA ladder, P: positive control,
R. equi ATCC6939, N: negative control (E. coli ATCC 25922), 1–10: R. equi 16S rRNA
positive samples.

Figure 2. vapA electrophoresis figure; M: 100bp DNA ladder, P: positive control, R. equi
ATCC 6939, N: negative control (E. coli ATCC 25922), 3 and 5: R. equi vapA positive
samples, 1,2,4,6: R. equi vapA negative samples.
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Table 1. PCR results of the R. equi isolates.
Specimen no

16S rRNA

vapA

vapB

20

+

-

-

33

+

-

-

53

+

+

-

56

+

-

-

57

+

+

-

60

+

-

-

61

+

-

-

77

+

-

-

82

+

-

-

90

+

-

-

[21] and it is thought to be between 10% and 20% in 0–6
months foals [22,23].
Clinical signs of REFP have slow progress and they
are difficult to detect until development of abscesses
in the lungs. Late onset of clinical symptoms may delay
prognosis by delaying the diagnosis and treatment. TBA
fluid culture method was known as a useful method for
diagnosis, however due to the possible antibiotic use or
the presence of different pathogenic microorganisms, this
method has been reported to be difficult to produce R. equi
from a single sample [24,25,26]. In a study investigating
the results of different sampling techniques, nasal swab
PCR (VP) sensitivity, specificity and disease incidence
were found to be 50%, 88%, and 18%, respectively for
R. equi VP [27]. In another study performed with 117
foals to measure the diagnostic value of nasotracheal
and transtracheal aspiration techniques, nasotracheal
aspiration samples from 96 foals (61%) were obtained
from 96 samples, and 14 (66%) of 21 samples received R.
equi positive culture. In nasal swab cultures performed
to evaluate the contamination of nasotracheal aspirate
specimens of microorganisms in nasopharynx, 2 of
56 samples were found R. equi positive [28]. Since the
formerly reported in sufficient activity of TBA fluid
culture, nasal swab collection was chosen in this study for
more accurate identification. The NANAT selective media
was utilized occasionally in experimental research related
to R. equi [29,30]. The small (1–2 mm diameter), salmon
coloured, smooth and bright morphologies of all colonies
reproduced overlap with the results of the previous studies
in R. equi isolation [22,23,31,32].

isolates were resistant to cefoxitin, 70% were resistant to
kanamycin, amikacin, clindamycin and rifampin, 60% were
resistant to amoxicillin-clavulanic acid, clarithromycin
and erythromycin. In conclusion, 60% of R. equi (n = 10)
isolates were detected 50% susceptible to streptomycin,
amoxicillin and erythromycin. The isolates no. 56, 57, 60,
and 90 (n = 4) developed multiple antibiotic resistance
against 11 antibiotics used in this study.
4. Discussion
R. equi foal pneumonia (REFP), which is widespread all
over the world, can be either endemic or sporadic on some
farms [5,20]. In farms where REFP is endemic, there are
significant differences between the cumulative incidence

Table 2. MIC values indicating antibiotic susceptibility of R. equi (n = 10) isolates.

Antibiotics

MIC value (µg/mL)
0.06 0.12 0.25 0.5 1

2

4

1

2

2

2

1

1

Amoxicillin
Streptomycin

1

Kanamycin
Amoxicillin clavulanic acid

2

8

1

1

2

1

16

32

128 256

4

1

3

2

1

4

2

3

3

3

3

2

Amikacin

64

1
1

MIC 50
(µg/mL)

MIC 90
(µg/mL)

MIC range
(µg/mL)

≤4

≥64

1–128

≤4

64

0.5–64

≤64

≥128

4–256

≤64

128

1–128

≤64

≥128

4–256

Clarithromycin

1

2

1

2

3

1

≤8

≥16

1–32

Azithromycin

2

1

1

1

2

3

≤8

32

1–32

Cefoxitin

1

1

1

4

2

≤16

≥32

1–64

1

4

2

≤8

16

1–16

1

4

2

≤8

16

1–16

1

4

≤2

16

0.25–16

Clindamycin

2

Rifampin

3

Erythromycin

2

1
1

2

1
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In some studies, the 16S rRNA PCR method was found
more sensitive than the culture method in the detection of
R. equi from clinical specimens [16,33]. In another study in
which species-specific DNA amplification was performed
with similar methodology, 3 and 9 R. equi positive results
were obtained from 98 nasal swab samples taken from adult
horses and 43 nasal swab samples taken from foals, with a
prevalence of 4.08% for adult horses and 25.58% for foals,
respectively [16]. In our study, the prevalence of R. equi in
foals was found to be lower, however the results underscore
the lack of sensitivity of standard culture techniques for
the diagnosis of R equi. A major step in understanding
the virulence mechanisms of R. equi infection has been
taken by the discovery of vap family genes [34,35]. These
genes give R. equi the ability to multiply in macrophages
and prevent phagosome formation. Although R. equi is
generally isolated from healthy horses and soil, detection
of virulence-related genes is important in characterizing
the pathogenicity of R. equi infections [36]. Many studies
have linked the vapA gene with R. equi pathogenicity and
lethality in foals [34,37,38], and this gene has been used
in epidemiological studies of pathogenicity in horses and
humans [39].
R.equi core genomes were described in 2016 [40].
VapA is an important immunity inducing protein and a
study stated that vapA and bacterin hyperimmune serum
administration in mares’ foals effectively protected foals
against R. equi challenge in Turkey [41]. Another vaccine
research conducted in Turkey reported that bacterin
+ vapA + IMS combined vaccines were found useful to
protect mice against R. equi infection [42]. In our study, 2
of 10 samples with 16S rRNA species identification were
found to be vapA positive and virulent R. equi incidence
was calculated as 20%. In our study, vapB gene was not
detected in PCR amplification in 10 samples that were
identified by molecular method. In a study performed
earlier in Marmara region of Turkey, 2 animals perished
on 2 distinct stud farms independent with the serological
screening research, and virulent R. equi was identified
from lesions of the six dead foals. The entire isolates had
R. equi specific antigens virulence plasmids [43]. The
data represented that virulent R. equi was prevalent in
Thoroughbred foals in the Marmara Region as indicated
in this study. In a recent study conducted in Şanlıurfa
province of Turkey, 4.0% of R. equi isolates from fecal and
environmental samples were found vapA-positive and
expressed 85 kb type-I plasmid from feces of the foals [44].
However, R. equi could not be detected from nasal samples
in contrary to this research.
Although most of the R. equi strains sampled from the
foals were greatly susceptible to macrolides and rifampin,
strains with resistance to both classes of antibiotic have been
reported. The use of rifampin alone is not recommended as
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it will accelerate resistance formation [37,45]. Resistance
development is associated with mutation in the rpoB
gene encoding the RNA polymerase ß-subunit [46,47]. In
another study, the prevalence of resistance to erythromycin
and rifampin was found to be 4% in samples collected
from foals in the states of Florida and Texas for 10 years.
The mortality rate of foals infected with resistant strains
was found 7 times higher [47]. In addition, the same
study suggested that some strains of R. equi sensitive to
macrolides were misclassified as resistant.
Resistant strains have been reported due to the
widespread use of macrolides and rifampin in foals
with subclinical disease [48,49]. Burton et al. [50] found
macrolide and rifampin-resistant isolates in 14 of 38
samples collected from a farm in the state of Kentucky. In
the same study, the incidence of resistance was found to
be 24% in foals that did not begin treatment and 62% in
treated foals. In a study conducted by Riesenberg et al. [51]
with 200 R. equi isolates, 3% of R. equi samples were found
resistant against rifampin. The treatment of foals with
diarrhoea during macrolide therapy or of foals infected
with macrolide-resistant strains is controversial due to
the deficient availability of alternative antimicrobials.
Macrolide and rifampin resistant R. equi strains were found
to be sensitive to fluoroquinolones, aminoglycosides,
oxazolidinones and glycopeptide antibacterials in vitro [47,
52]. In a study, 18 of the 24 isolates were also susceptible
to chloramphenicol, tetracycline and trimethoprim
sulfamethoxazole [47].
The reports about recommended antimicrobials for the
therapy of foals infected with macrolides and rifampinsusceptible strains are deficient. Despite the lack of data,
many different classes of antimicrobials have been used to
cure R. equi infections in foals. Anecdotal information is
available that oral doxycycline treats R. equi pneumonia in
foals when used together with rifampin. Doxycycline and
rifampin show a strong synergistic effect against R. equi
especially in in vitro conditions [53]. In our study, one of
the two vapA positive isolates was resistant to 11 antibiotics
and the other isolate was resistant to seven antibiotics. The
presence of clarithromycin, azithromycin and rifampin
resistance in isolates is consistent with previous studies
[48–50].
Considering the results of this study, the presence of
R. equi has been revealed among horse population in the
North Aegean and Marmara regions, Turkey. Further
epidemiological studies are needed to determine virulent
plasmids and antibiotic resistance profiles by analyzing
virulent R. equi in other regions of horse farms of our country.
Identification of the infection in horses and the correct use
of appropriate antibiotics will benefit the breeding and the
national economy. For this reason, it is recommended that
veterinarians and farm administrations should confirm
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the R. equi diagnosis especially by molecular methods, if
possible, from nasal swab before applying treatment to foals
that do not show clinical pneumonia, and make a detailed
examination of the clinical picture of the foal.
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